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Down syndrome (DS) is the most commonly identifiable genetic form of intellectual
disability. Individuals with DS have considerable deficits in intellectual functioning (i.e.,
low intellectual quotient, delayed learning and/or impaired language development)
and adaptive behavior. Previous pharmacological studies in this population have
been limited by a lack of appropriate endpoints that accurately measured change
in cognitive and functional abilities. Therefore, the current longitudinal observational
study assessed the suitability and reliability of existing cognitive scales to determine
which tools would be the most effective in future interventional clinical studies.
Subtests of the Repeatable Battery for the Assessment of Neuropsychological
Status (RBANS), Cambridge Neuropsychological Test Automated Battery (CANTAB),
and Clinical Evaluation of Language Fundamentals-Preschool-2 (CELF-P-2), and the
Observer Memory Questionnaire-Parent Form (OMQ-PF), Behavior Rating Inventory of
Executive Function®–Preschool Version (BRIEF-P) and Leiter International Performance
Scale-Revised were assessed. The results reported here have contributed to the
optimization of trial design and endpoint selection for the Phase 2 study of a new selective
negative allosteric modulator of the GABAA receptor α5-subtype (Basmisanil), and can
be applied to other studies in the DS population.
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INTRODUCTION
Down syndrome (DS) is the most common chromosomal cause
of intellectual disability (ID). Each year approximately 6000
babies are born in the United States with DS, which is equivalent
to 1 in 700 babies (Parker et al., 2010). Worldwide the estimated
incidence is approximately 1 in 1000–1100 (World Health
Organization (WHO), 2015). DS is characterized by substantial
limitations in intellectual functioning (i.e., low intellectual
quotient (IQ), delayed learning and/or impaired language
development) and adaptive behavior. Studies have revealed
a specific neuropsychological profile for this population—
individuals typically have an average IQ below 70 (Chapman and
Hesketh, 2000; Gioia et al., 2000) and weaknesses consistently
associated with associative and verbal working memory (Jarrold
et al., 2006, 2008; Silverman, 2007), episodic memory and
explicit long-term memory (Carlesimo et al., 1997; Vicari,
2001), expressive language (Miller, 1998), and executive function
(Lanfranchi et al., 2010), whereas relative strengths have been
observed in visuospatial tasks and implicit long-term memory
(Edgin et al., 2010b). Although, IQ levels vary in individuals with
DS, most individuals function in the mild to moderate range
of ID (Centers for Disease Control Prevention, 2015; Centers
for Medicare Medicaid Services, 2014). Of note, as the rate
of cognitive development progressively becomes slower over
the childhood years in relation to typically developing peers, a
decline in IQ scores over the childhood years is also observed
(Carr, 1995).
Differences in brain structure and function are already
apparent in early infancy in individuals with DS (Nadel, 2003;
Edgin et al., 2015), with clear alterations in hippocampus
(e.g., altered microarchitecture of pyramidal cells), prefrontal
cortex (reduced volume), and cerebellum (e.g., hypoplasia)
apparent pre- and post-natally (Pennington et al., 2003; Lott
and Dierssen, 2010). Furthermore, structural and volumetric
magnetic resonance imaging (MRI) studies have shown that
individuals with DS have a smaller intracranial volume than their
typically developing peers, with the most profound differences
observed in the frontal lobes, cerebellum, and brainstem (Kesslak
et al., 1994; Raz et al., 1995; Aylward et al., 1999). Other studies
have also shown that smaller volumes are observed in the
temporal lobe, including the hippocampal region (Schmidt-Sidor
et al., 1990; Pinter et al., 2001) which is known to affect a range
of cognitive functions. As individuals with DS approach early
adulthood, some are at particular risk for the early development
of Alzheimer’s disease (Zigman et al., 2008). The prevalence of
dementia in DS increases over 45 years of age, with upwards of
75% having dementia over 65 years (Lott and Dierssen, 2010),
although neuropathological and neurochemical changes have
been observed as early as fetal development (Bahn et al., 2002;
de Sola et al., 2015).
Recent advancements in our understanding of the underlying
mechanisms of cognitive dysfunction in DS suggest an
imbalance between excitatory and inhibitory neurotransmission.
G-Aminobutyric acid (GABA) neurotransmission is the major
inhibitory system in themature brain. Reducing GABA-mediated
inhibition by limiting GABAA receptor activity has shown
beneficial effects on hippocampal synaptic plasticity as well as
learning and memory deficits in the Ts65Dn mouse model of DS
(Kleschevnikov et al., 2004; Fernandez et al., 2007; Colas et al.,
2013; Martínez-Cué et al., 2013; Potier et al., 2014). A negative
allosteric modulator of the GABAA α5-containing receptor
subtype (Basmisanil) is currently under investigation in young
adults with DS (ClinicalTrials.gov identifier: NCT02024789).
Previous pharmaceutical trials in DS have noted that studies
are often limited by a lack of endpoints that accurately captured
cognitive and functional changes (Heller et al., 2006). Thus, it is
important to assess the suitability and reliability of existing tools
that measure cognitive function in a longitudinal observational
study to determine which measures may be most effective
in the context of a pharmacological clinical trial. Specifically,
clinical trials require measures that can be repeatedly and reliably
administered across international sites, to participants of a
defined age range, and that do not exhibit large practice, floor,
or ceiling effects.
The recently published TESDAD battery includes
neurocognitive tests and scales, but no test-retest analysis
or evaluation of potential practice effect are currently available
(de Sola et al., 2015). Edgin et al. also reported the development
of the Arizona Cognitive Test Battery (ACTB) based on
the Cambridge Neuropsychological Test Automated Battery
(CANTAB) and other available tools (Edgin et al., 2010a). The
ACTB was designed based on historical findings of performance
deficits in domains, and tasks that had been repeatedly shown
to be more difficult for those with DS (Pennington et al.,
2003; Edgin et al., 2010a, 2014; Lee et al., 2011). The ACTB
validation suggested that neuropsychological measures could
be administered to a large sample of individuals with DS
(n = 74) with low floor effects and good preliminary estimates
of test-retest reliability (albeit in a small subsample). This battery
could have been used in our clinical trials; however, based on
the mechanism of action of Basmisanil, some of the tests may
be more relevant than others (e.g., hippocampal or prefrontal
tests vs. cerebellar function tests). Therefore, alternative scales
were chosen for analysis in this study. Furthermore, most
measurement validation studies have been limited in their
ability to ascertain the reliability of endpoint measures within
the retesting time frame and frequency required to determine
how the measures perform in a clinical trial context. Given
the frequency of new clinical investigations in this population,
more measurement development and validation is urgently
required, leading us to report on these data to assist the broader
community with study design in the future. Furthermore, the
National Institutes of Health (NIH) Research Plan on Down
Syndrome, which was revised in 2014, reports on the need to
study clinical and behavioral treatments and interventions for
DS, with part of this plan noting the importance for reliable
and valid endpoint assessments to measure the efficacy of these
treatments (U.S. Department of Health Human Services National
Institutes of Health, 2014).
OBJECTIVES
Given this background, the primary objective of this non-
pharmacological study (BP25612; ClinicalTrials.gov identifier:
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NCT01580384) was to investigate the suitability (i.e., number
of participants completing the tests, floor/ceiling effects, and
potential learning effect) of selected neurocognitive tests in
a 6-month longitudinal and multinational setting for the
measurement of cognitive function in individuals with DS.
Subtests of the Repeatable Battery for the Assessment of
Neuropsychological Status (RBANS) (Randolph et al., 1998),
subtests of CANTAB (Cantab Research Suite, 2015), subtests
from the Clinical Evaluation of Language Fundamentals-
Preschool-2 (CELF-P-2) (Pearson, 2004), the Observer Memory
Questionnaire-Parent Form (OMQ-PF) (Gonzalez et al., 2008),
and the Behavior Rating Inventory of Executive Function R©–
Preschool Version (BRIEF-P) (Gioia et al., 2000) were used to
assess immediate and delayed memory, language, and executive
function. Secondary objectives were to assess the test-retest
reliability of these measures over 6 months and to explore the
influence of age (adolescents vs. adults) and non-verbal IQ
level, as measured by the Leiter International Performance Scale-
Revised (Leiter-R) (Roid and Miller, 1997).
Part of the results from this study were previously
presented at the 2014 American Association of Intellectual and
Developmental Disabilities (AAIDD) Annual Meeting (del Valle
Rubido et al., 2014), as well as at the 2013 Cognition in Down
Syndrome Workshop (Liogier d’Ardhuy et al., 2013). Results
from the assessments using the Vineland Adaptive Behavior
Scales-II (VABS-II) and the Clinician Global Impression of
Severity (CGI-S) and Improvement (CGI-I) scales will be
reported separately.
METHODS
This was a 6-month (24–27 weeks) observational, non-
pharmacological, longitudinal, multicenter (11 sites),
multinational study in adolescents (12–17 years) and adults
(18–30 years) with DS conducted between February 2012 and
January 2014. The study was conducted in the United States,
United Kingdom, Spain, France, Italy, Canada, and Argentina.
Overall 90 participants (equally split between adolescents and
adults) were planned to be enrolled and randomized into three
different schedules of assessments (i.e., A, B, and C; C contained
a smaller number of tests and visits). In order to include all of the
planned assessments and keep the duration within the desired
90-min testing period for each study visit, three schedules of
assessments were implemented. A 15–25min break was planned
after 45min of testing and an additional break could be added
before starting the last exercise (RBANS) if requested or deemed
necessary by the rater. Randomization was stratified by age
group to have a balanced number of sequences of assessments
between adolescents and adults.
The current study was conducted for 6 months to reflect the
clinical trial design of the ongoing Phase 2 study. Participants
who met the inclusion criteria (below) received testing at the
baseline visit, 4 weeks and 24 weeks later when randomized to
schedule A or B or received testing at the baseline visit and at 24
weeks when randomized to schedule C (Table 1). These schedules
resulted in a common data set that was administered to at least 60
TABLE 1 | Number of participants per randomization schedule and total
number of subjects evaluated per task.
Scale Subscale Schedule Total number of
participants
A B C
Leiter-R 30 30 30 90
CANTAB SSP 30 30 60
CELF-P-2 30 30 30 90
RBANS List learning 30 30 30 90
Story memory 30 30 30 90
Picture naming 30 30 30 90
Semantic fluency 30 30 30 90
OMQ-PF 30 30 30 90
BRIEF-P 30 30 60
Randomization was stratified by age, with an equal number of participants in the 12–17
and 18–30 years age groups. For schedules A and B assessments were done at baseline,
week 4 and week 24. For schedule C assessments were done at baseline and week 24
only.
participants. The total duration of the study for each participant
was between 24 and 27 weeks.
Study Population
Male and female adolescents (12–17 years) and adults (18–30
years) with a diagnosis of DS were included in the study if they
met all of the following criteria: parent/caregiver was able to
speak and understand the local language, to accompany the
participant to all clinic visits, and to provide information
about the participant’s behavior and daily functioning.
Also, the participant’s speech was understandable to the
examiner; at screening the participant attempted to perform
the neuropsychological tests; stable treatment for at least 8
weeks prior to screening if he/she had a generalized anxiety
disorder, major depressive disorder, autism spectrum disorder,
attention-deficit/hyperactivity disorder, and recent laboratory
tests confirming euthyroid (serum free thyroxine [FT4] and
thyroid stimulating hormone [TSH]) and normoglycemic
(serum glucose) status (within 12 months prior to screening
visit, with or without treatment). Individuals were not included
if they met any of the following criteria: diagnosed with axis
I and II psychiatric disorders, except those mentioned above;
exhibited significant suicidal risk; could not comply with
protocol or perform the outcome measures due to hearing
or visual impairment; had evidence of dementia; had thyroid
dysfunction or diabetes not adequately controlled at least 8
weeks prior to randomization; or abused alcohol and/or other
substances.
Written informed consent was obtained from the
parents/caregivers and assent from the participants prior
to participation in the study. The study was conducted in
accordance with the principles of the Declaration of Helsinki and
Good Clinical Practice (GCP), and all required approvals were
obtained from the appropriate independent ethics committee
(IEC)/institutional review board (IRB) prior to the start of the
study.
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Concomitant Medication
Psychotropic agents that would likely interfere with any of the
assessments could not be initiated or changed during the study
period. This included antidepressants (e.g., selective serotonin
reuptake inhibitors [SSRIs], serotonin and norepinephrine
reuptake inhibitors [SNRIs], norepinephrine-dopamine
reuptake inhibitors such as bupropion, and serotonin-
norepinephrine reuptake inhibitors such as the tricyclic
antidepressants), antipsychotics, benzodiazepines and hypnotics,
acetylcholinesterase inhibitors, GABA agonists (e.g., tiagabine,
vigabatrin, and baclofen), and glutamatergic drugs (e.g., riluzole,
topiramate, memantine, and lamotrigine).
Procedures
Selected raters for the cognitive assessments/rating scales were
provided with instructions and comprehensive training on scale
administration prior to the start of the study. Whenever possible,
for each participant the same rater/caregiver consistently
administered/completed the rating scales across study visits.
The assessments were completed in a prespecified and
consistent order to maximize standardization across sites and
participants.
Scales Selected to Measure Cognitive
Skills
The Leiter International Performance Scale-revised
(Leiter-R) (Roid and Miller, 1997)
Leiter-R, a non-verbal intelligence test, was individually
administered to all participants. Two reasoning subtests
(Sequential Order and Repeated Patterns) and two visualization
subtests (Figure Ground and Form Completion) were
administered to derive a non-verbal IQ.
Repeatable Battery for the Assessment of
Neuropsychological Status (RBANS) (Randolph et al.,
1998)
The RBANS was individually administered and used to measure
cognitive changes over time. Four subtests of the full battery of
12 subtests were used in this study to assess immediate memory
(List Learning and Story Memory), as well as language capacities
(i.e., Picture Naming and Semantic Fluency). The RBANS was
chosen because it has been used in clinical trials investigations
(Duff et al., 2010; Hobson et al., 2010) and provides four alternate
forms. Alternate forms were used on each study day. The raw
score on each of these scales was used for analysis.
Cambridge Neuropsychological Test Automated
Battery (CANTAB) (Cantab Research suite, 2015)
The CANTAB is a computerized battery of neuropsychological
tests carried out by the participant under the supervision of
qualified personnel. The Spatial Span (SSP) subtest was used in
this study to assess working memory capacities; it is considered a
visuospatial analog of a digit span test in which a random array
of boxes on a screen change color in a particular sequence. The
participant’s response was given by recalling the test pattern in
forward or reverse order.
Observer Memory Questionnaire-parent Form
(OMQ-PF) (Gonzalez et al., 2008)
The OMQ-PF is a 27-item questionnaire designed to ascertain
the perceptions of parents/caregivers about the participant’s daily
memory function. It has been previously validated in children
with temporal lobe epilepsy and memory impairment (Gonzalez
et al., 2008). Items were rated on a 5-point Likert scale (1-
strongly agree to 5- strongly disagree OR 1- never to 5- always).
Behavior Rating Inventory of Executive
Function®–Preschool Version (BRIEF-P) (Gioia et al.,
2000)
The BRIEF-P was completed by the parent/caregiver
and measured the participant’s everyday skills associated
with executive function (i.e., Inhibit, Working Memory,
Plan/Organize, and the Global Executive Composite [GEC]).
This scale has been used in a number of investigations of
DS, where it demonstrated a unique pattern of strengths and
weaknesses, including deficits in parent’s ratings of working
memory and planning, but not in inhibition or emotional
control (Lee et al., 2011).
Clinical Evaluation of Language
Fundamentals-Preschool-2 (CELF-P-2) (Pearson,
2004)
The CELF-P-2 consists of a variety of subtests used to evaluate
the language skills of preschool-aged children (3–6 years). The
Word Classes subtest was used to evaluate the participant’s ability
to understand and express relationships between semantically
related words. Raw scores from the receptive and expressive
scales of this subtest were used in the analyses.
The CELF-P-2, RBANS, and OMQ-PF were translated into
French, Italian, and Spanish by a process that included forward
translation, back translation, and concept validation. Rater
instructions for the Leiter-R and CANTAB were also translated.
The BRIEF-P was already available in various languages and did
not require translation for use in this study.
Statistical Methods
For the assessments with a minimum of 60 participants, a Mixed
Model Repeated Measurements (MMRM) analysis was applied
with visit-time as repeat factor; subject as subject-effect; gender,
language and age as class factors; age by visit-time as interaction;
and baseline IQ as continuous covariate. Estimates of the mean
differences between age groups, genders and visits (6 months vs.
baseline), and the estimate of the slope (β) over IQ were derived.
Measurements of between-subject variability and residual
variability as well as of correlation between repeated assessments
within the same subjects were extracted from the mixed model.
As a measure of test-retest reliability, Intraclass Correlation
Coefficient (ICC) was derived per each age group between visits
(6 months vs. baseline). An ICC was considered poor, fair, good,
and very good when values were <0.40, 0.40–0.59, 0.60–0.75,
and >0.75, respectively (Cicchetti and Sparrow, 1981; Oremus
et al., 2012). Analyses of correlation at baseline were performed
between RBANS List Learning and both CELF-P-2 Expressive
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and OMQ-PF scores, and between CANTAB SSP reverse and
BRIEF-P scores (i.e., GEC and Working Memory subdomains).
All derived p-values were not controlled for multiple
comparisons and should be interpreted as an aid to gauge the
magnitude of estimated differences.
RESULTS
Study Population
A total of 94 participants were screened, 90 were randomized
(49 adolescents 12–17 years; 41 young adults 18–30 years), and
89 completed the study; the participant who did not complete
the study was lost to follow up. Table 2 shows the study
demographics. The mean age for the adolescent and adult groups
was 15 years and 23 years, respectively. The adult group was well
balanced for gender (51% female, 49% male), whereas slightly
more males were enrolled in the adolescent group (59%). No
procedure-related adverse events (e.g., fatigue or tiredness) were
recorded in any participants.
Neurocognitive Assessments
The baseline IQ scores are shown in Table 2. The mean IQ scores
were similar between age groups (adolescents 42± 7; adults 39±
6), although 22% of adolescents and 61% of adults performed at
the floor (36) of the test (Table 3).
Memory Assessments
RBANS (List Learning and Story Memory)
The List Learning baseline scores followed a relatively normal
distribution, ranging from 0 to 32, over a maximum possible
score of 40, with means of 11.8 (standard deviation [SD] 7.5)
and 13.8 (SD 8.2) for the adolescents and adults, respectively
TABLE 2 | Study demographics.
12–17 years 18–30 years
N 49 41
Females 20 (41%) 21 (51%)
Males 29 (59%) 20 (49%)
AGE
Mean ± SD 14.5 ± 1.6 22.7 ± 3.4
Median 15 22
Range 12–17 18–30
IQ (LEITER-R)
Mean ± SD 41.6 ± 7.1 39.0 ± 6.0
Mean (F/M) 39.9/42.7 40.4/37.6
Range 36–80 36–65
COUNTRY (N)
Argentina 7 3
Canada 2 6
France 17 6
Italy 6 5
Spain 11 6
UK 0 2
US 6 13
(Table 4). Very few participants had a score of zero in
this task (Table 3; 4 and 7% for adolescents and adults,
respectively). However, 24% of adolescents and 12% of adults
had very low scores (≤4). The average reference List Learning
scores for typically developing individuals aged 20–39 years
is approximately 30 (Randolph, 2006). Overall, adults had
statistically higher List Learning scores than adolescents (age, p =
0.035; Table 5). The adolescents showed improvement (+2.3 ±
5.6) over the 6-month period, whereas the adults did not, as
captured by the close to significant time x age interaction. The
IQ scores were significantly related to the List Learning scores
(p < 0.001; Table 5).
Overall, the Story Memory scores ranged from 0 to 21 out of
a maximum possible score of 24 with means of 5.6 (SD 4.1) and
6.0 (SD 5.2) for the adults and adolescents, respectively (Table 4).
The distribution was skewed toward the lower scores, illustrating
a floor effect. This was particularly evident in the adolescent
group, with 22% obtaining a score of 0 at baseline, reflecting the
difficulty of this subtest for this population. However, on average,
both age groups performed equally in the Story Memory subtest
(p = 0.250; Table 4). Adolescents scores decreased on average
over the 6-month period (−1.6 ± 3.5 SD), whereas adult scores
did not change over time (time × age, p = 0.030; Table 5).
IQ scores were significantly related to the Story Memory scores
(p = 0.001; Table 5).
OMQ-PF (Daily Memory)
The baseline distributions of total raw scores for both age groups
appeared normal, ranging from 61 to 124 (reference for typically
developing children 5–16 years of age, 107). There was no
significant difference in the observed memory scores between age
groups (6.09, p = 0.075) or visits (0.21, p = 0.824; Table 5).
IQ level did not predict perceived daily memory scores. The
observedmemory score correlated with the RBANS List Learning
score across ages (r = 0.33, p < 0.01), demonstrating concurrent
validity with a direct memory assessment.
Executive Function Assessments
CANTAB (Spatial Span)
For the forward span length, the baseline distribution was normal
in both age groups and no floor effect was observed (Table 5). On
the other hand, in the reverse task, 24% of the adolescents and
22% of the adults scored 0. On average, adults had significantly
greater reverse span length (+0.77, p = 0.019; Table 5), whereas
no difference was observed between age groups for the forward
span performance (age, p = 0.095). Forward and reverse span
lengths were stable over time (age × time 0.814 and 0.435,
respectively; Table 5). IQ was related to both forward (p < 0.001)
and reverse (p = 0.001) span length (Table 5).
BRIEF-P
At baseline, the BRIEF-P GEC scores in the adolescent group
were normally distributed, whereas the adult group peaked at
lower values (better). Adults had statistically lower mean BRIEF-
P GEC scores compared with adolescent (−13.42, p = 0.011),
indicating higher perceived executive functioning in this age
group. GEC scores were stable across visits (time, p = 0.291).
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TABLE 3 | Test-retest reliability (ICC) between baseline and 6 months and floor effect at baseline.
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Adolescents ICC NA 0.78 0.71 0.63 0.67 0.53 0.76 0.50 0.59 0.69 0.69
Floor* 11/49 (22%) NA 7/49 (14%) 1/49 (2%) 1/34 (3%) 8/34 (24%) NA 5/49 (10%) 3/49 (6%) 2/49 (4%) 11/49 (22%)
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TABLE 4 | Mean scores and standard deviations at baseline and 6 months
for each scale.
Mean ± SD (N) 12–17 years 18–30 years
RBANS list learning Baseline 11.8 ± 7.5 (49) 13.8 ± 8.2 (41)
6 Months 14.1 ± 7.3 (49) 13.8 ± 7.0 (39)
RBANS story memory Baseline 6.0 ± 5.2 (49) 5.6 ± 4.1 (41)
6 Months 4.4 ± 3.4 (49) 5.5 ± 4.3 (39)
RBANS picture naming Baseline 6.3 ± 2.3 (49) 6.4 ± 2.1 (41)
6 Months 6.4 ± 2.4 (49) 6.7 ± 2.7 (39)
RBANS semantic fluency Baseline 8.1 ± 5.1 (41) 7.2 ± 3.7 (49)
6 Months 6.6 ± 4.1 (39) 6.3 ± 3.0 (49)
CANTAB SSP length (forward) Baseline 3.5 ± 1.0 (27) 3.2 ± 1.1 (33)
6 Months 3.6 ± 0.9 (26) 3.3 ± 1.3 (33)
CANTAB SSP length (reverse) Baseline 2.5 ± 1.7 (27) 2.2 ± 1.4 (33)
6 Months 2.8 ± 1.2 (26) 2.2 ± 1.4 (33)
CELF-P-2 (expressive) Baseline 9.0 ± 5.6 (49) 12.9 ± 5.7 (41)
6 Months 10.5 ± 5.5 (49) 12.0 ± 6.5 (39)
CELF-P-2 (receptive) Baseline 14.5 ± 4.8 (49) 16.3 ± 4.6 (41)
6 Months 14.8 ± 4.6 (49) 15.7 ± 6.0 (39)
BRIEF-P (composite) Baseline 104 ± 16.4 (34) 92.1 ± 20.9 (27)
6 Months 101 ± 16.0 (34) 91.2 ± 20.8 (26)
OMQ-PF Baseline 94.4 ± 13.0 (49) 99.1 ± 13.0 (34)
6 Months 93.9 ± 17.0 (48) 100 ± 14.3 (37)
IQ was not related to GEC scores (p = 0.931, Table 5). To
further explore this lack of influence of IQ, correlations between
IQ scores and the Working Memory domain, the Plan/Organize
and the Inhibit domains were conducted and did not show any
relation, in either age group. No significant correlations were
found between BRIEF GEC scores and either forward or reverse
span lengths from the CANTAB SSP tasks. Nevertheless, BRIEF-
P Working Memory scores correlated with reverse SSP length
(R = −0.27, p = 0.036, moderate effect).
Language Assessments
RBANS (Picture Naming and Semantic Fluency)
The baseline distribution of scores for both subtests followed
normal distribution for both age groups, and a small number
of participants performed at the floor of the tests (Table 3). No
age differences were detected. Whereas, no effect of time was
noticed in the Picture Naming task, time had a significant effect
on Semantic Fluency results with lower scores at 6 months than
at baseline (-1.17, p < 0.001, Table 5). Both Picture Naming and
Semantic Fluency scores were significantly related to IQ (p =
0.005 and p = 0.006, respectively).
CELF-P-2 (Linguistic Functioning)
The baseline distribution of total scores in the CELF-P-2 was
normal for the adolescents but was skewed toward the higher
values for adults. This is likely due to a significant number
of adult participants (n = 12) reaching the maximum score
(or close to) of 20 for the receptive domain (but not for the
expressive). Of note, female participants had a statistically higher
average total scores (+3.95, p = 0.037) and expressive scores
(+2.51, p = 0.016) than males. No gender differences were
observed in receptive scores, likely due to the ceiling effect in
this domain. Time did not affect any of the CELF-P-2 sub-
scores. The total CELF-P-2 scores were significantly related to
IQ scores (p = 0.001), driven by both the expressive and the
receptive domains (p = 0.003; p = 0.024, respectively). To
better understand the minimum level of language skills required
to perform key cognitive tasks, we tested for correlations between
receptive and expressive components of the CELF-P-2 and the
RBANS List Learning and Semantic Fluency scores. In both
age groups, CELF-P-2 expressive scores highly correlated with
RBANS Semantic Fluency scores (p < 0.001) and with RBANS
List Learning scores (Figure 1).
Test-retest Reliability
A summary of ICCs for all scales is shown in Table 3. Reliability
ranged from fair (ICC 0.40–0.59) to very good (ICC > 0.75).
Most of the scales depicted good reliability (ICC = 0.63:
CELF-P-2, RBANS Semantic Fluency, List Learning and Story
Memory subtests, BRIEF-P and OMQ-PF). The highest ICC
scores were found for the BRIEF-P and OMQ-PF, which are both
parent-reported scales.
DISCUSSION
This study assessed a variety of neurocognitive tests and
functioning scales over a 6-month period to determine
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TABLE 5 | Estimates of differences for each assessment and influence of Time, Age, and IQ (p-values as from MMRM analysis).
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ESTIMATES
6 Months –Baseline −1.79 0.39 −0.08 0.16 0.25 0.21 0.16 −1.17 1.20 −0.81
Adults –Adolescents −13.42 2.15 1.16 0.43 0.77 6.09 0.30 0.87 3.17 1.03
Females—Males −0.63 2.51 1.30 −0.22 −0.25 2.80 0.71 1.82 2.09 0.74
TESTS OF EFFECTS
Time 0.291 0.373 0.844 0.147 0.155 0.824 0.513 <0.001 0.051 0.025
Age 0.011 0.056 0.261 0.095 0.019 0.075 0.519 0.297 0.035 0.250
Time × Age 0.684 0.014 0.387 0.814 0.435 0.387 0.752 0.417 0.078 0.030
IQ 0.931 0.003 0.024 <0.001 0.001 0.331 0.005 0.006 <0.001 0.001
Bold values correspond to p < 0.05.
FIGURE 1 | RBANS List Learning scores and CELF-P-2 Word Classes
expressive scores.
appropriate outcomemeasures for potential use in interventional
pharmacological and non-pharmacological treatment studies in
adolescents and young adults with DS. To date, this is the largest
data set reporting evaluation of these assessments.
The Leiter-R IQ scale is a non-verbal assessment that is
not influenced by linguistic production which is particularly
impaired in individuals with DS. Moreover, in an international
clinical trial context, form equivalence after language translation
is amajor barrier to the implementation of IQ scales. The Leiter-R
is not influenced by this issue. Our results show that the Leiter-
R may not be the most suitable means of capturing the lower
end of the IQ range in DS as 22% of adolescents and 61% of
adults scored at the floor of the test (36); however, this test has
shown better results than those obtained in a previous clinical
trial with the abbreviated Stanford-Binet Intelligence Scales Fifth
Edition (ClinicalTrials.gov Identifier: NCT01436955). Based on
these observations, the Leiter-3 (Roid and Miller, 1997) was
administered in a study with 180 adults and adolescents with DS
(Clinical.Trials.gov Identifier NCT01920633). These results are
more promising in terms of data distribution and percentage of
participants at the floor of 30 (approximately 1%). This suggests
that the Leiter-3 is probably more appropriate to measure the full
IQ range in this population (Figure 2). In studies in children with
DS, it is not uncommon for standardized IQ scores to decrease
across childhood (Carr, 1995). In our study of older individuals
with DS (12–30 years), using the Leiter-R we found stability in
IQ scores similar to the recent findings by Carr, showing no
change in IQ from 21 to 45 years in a longitudinally collected
sample(Carr, 2012). However, with the greater number of adults
at the floor of 36, any age-related differences may have been
masked by floor effects.
The RBANS was developed for the dual purposes of
identifying and characterizing abnormal cognitive decline in
older adults and as a neuropsychological screening battery
for younger patients (Randolph et al., 1998). With average
List Learning scores of 14 for adults with DS where the
average score in typically developing peers is approximately
30, and even greater discrepancies in the Story Memory
subtest, this demonstrates that these tasks are very difficult for
individuals with DS. Some improvements in performance were
observed over the 6-month study period and, in particular,
adolescents showed improvement in the List Learning task. These
observations may be linked to the natural neurodevelopment of
the capacities of adolescents and/or the fact thatmore adolescents
withDS are attending school and involved in alternative therapies
such as speech therapies and educational resources. The Story
Memory scores, however, did not show a similar improvement
in adolescents which may be due to a greater floor effect.
Observed memory is not a direct measure of the participant’s
memory capacities, but a functional measure that can be affected
by many facets of mnemonic ability in daily life. Overall,
the OMQ-PF showed good reliability and suitability for use
in clinical trials of individuals with DS. Previous results by
Gonzales et al. have indicated that the OMQ-PF may be more
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FIGURE 2 | IQ scores: distributions using three different IQ scales. The horizontal bar represents the median score.
closely related to new learning ability rather than retention or
recall of information (Gonzalez et al., 2008), and other studies
suggest that everyday abilities cannot necessarily be inferred
from direct neuropsychological tasks (Chaytor and Schmitter-
Edgecombe, 2003). Our results suggest that observed memory
scores relate to specific memory functions, as illustrated by the
correlation noted between the RBANS List Learning immediate
and OMQ-PF scores.
Forward and backward SSP subtests were administered to
assess workingmemory. Here we recapitulate the knownworking
memory deficit in DS (Lanfranchi et al., 2012), with low scores
in both forward and reverse tasks and a significant number of
participants scoring 0, or “floor” effects, in the reverse task.
Both subtests were statistically related to IQ scores, however,
this relationship is likely driven by the floor effects in both IQ
and spatial span tests, and thus less meaningful. Neither forward
nor reverse SSP length correlated with BRIEF-P GEC scores.
Overall, these findings together with low ICC values indicate
that SSP would be too difficult and discouraging for individuals
with DS and have limited usefulness as an outcome measure in
interventional clinical trials.
The BRIEF-P was implemented as an indirect measure of
executive function, including working memory function. Here
again executive function deficits were clear, confirming the
neurocognitive DS profile. An obvious difference was evident
between the adolescent and adult groups in GEC scores, with
adults performing significantly better than adolescents. Adult
performance reached maximum scores, suggesting that the
preschool version of the BRIEF is probably less appropriate for
the adults than the adolescents with DS. The BRIEF-school age
version (5–18 years) could have been used instead. This version
of the BRIEF was indeed used as a behavioral assessment to
establish concurrent validity for the ACTB (Edgin et al., 2010a).
The perceived global executive function was not influenced
by IQ across ages. We therefore looked at IQ correlations
in adolescents and adults separately in BRIEF-P subdomains
and interestingly noted that neither, the Working Memory,
Plan/Organize or Inhibit subtests correlated with IQ. However,
a focused analysis of Working Memory aspects, considered
to be a major contributor to executive function weaknesses
in DS, revealed that the Working Memory domain of the
BRIEF-P correlated with reverse SSP, a direct Working Memory
executive function measure. These findings suggest that the
BRIEF-P captures executive functions engaged in the reverse SSP
processing, but overall distinct functions than those captured by
the Leiter.
Language difficulties are one of the most prominent barriers
to independence and socialization and part of the neurocognitive
profile in DS. Here we assessed elements of linguistic functioning.
The CELF-P-2 Word Classes test showed a potential “ceiling”
effect, reducing its use to assess changes in language abilities
in a trial; nevertheless, the link between CELF-P-2 expressive
scores and RBANS List Learning performances suggests this test
could be of relevant use as a screening tool in future studies
to ensure enrolment of participants with the minimal level of
expressive language ability required to perform key cognitive
tasks. In our study, the verbal communication level was on
average better in females as compared to males, particularly
in the expressive domain, as assessed by the CELF-P-2 Word
Classes and RBANS Semantic Fluency, confirming the previously
described communication profile in DS (Määttä et al., 2006).
Language proficiency was also tested with the Picture Naming
and Semantic Fluency tasks from the RBANS. Overall, the test-
retest scores from these two tests were considered fair, illustrating
a potential lack of suitability for clinical trials in individuals with
DS. However, to avoid potential practice effects, four different
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TABLE 6 | Summary of key learnings.
Domain Test name Suitable for clinical trials Summary of main findings
with people with DS
12–17 years 18–30 years
IQ measurement Leiter-R No No - Floor effect observed at 36
Leiter-3 Yes Yes - No floor effect, good distribution
Memory RBANS—Short term memory - Differences between the forms
List learning Yes Yes - Good test-retest reliability, no floor effect, sensitive to age and IQ
Story memory No Yes - Floor effects and unstable over time in adolescents.
OMQ-PF Yes Yes - Good stability over time and good test-retest reliability
Executive function CANTAB SSP
Forward Yes Yes - No floor effect, good test-retest reliability, sensitive to IQ
Reverse No No - Floor effects in both age groups, low reliability
BRIEF-P Yes No - Reliable, stable and sensitive to age and detects impairment in the
working memory domain
- Ceiling effect in adults
Language CELF-P-2 Word classes Yes Yes - Stable, reliable and sensitive to age and IQ
- Ceiling effect in the receptive domain in adults (recommend to use CELF-4)
RBANS
Semantic fluency Yes Yes - No floor effect, sensitive to spoken language and IQ but not age
Picture naming No No - Low test-retest reliability
RBANS forms have been developed to be used on several
occasions in clinical trials. A weakness in our study is that
the same RBANS form was used at the baseline visit but two
different forms were used at the Week 24 visit depending on the
study schedule. This might explained the low ICC scores that we
observed or the time effect observed in the Semantic Fluency task.
Finally, we observed that direct measurements of immediate
memory, executive function and linguistic functioning as
described here, were all influenced by the IQ level of the
participants. On the other hand, indirect measures of executive
function andmemory as reported by the parents or the caregivers
(BRIEF-P and OMQ-PF) were not sensitive to the IQ level.
Table 6 summarizes the main findings for each scale
evaluated in this study and our conclusions on their suitability
for clinical trials with adults and adolescents with Down
syndrome. These conclusions contributed to the selection of
suitable outcome measures for the ongoing 26-week Phase 2
study (Clinicaltrials.gov identifier: NCT02024789) evaluating the
efficacy, safety and tolerability of Basmisanil in individuals (12–
30 years) with DS. RBANS List Learning was chosen as the
primary endpoint for evaluating hippocampal tasks associated
with a global functioning evaluation, whereas the Leiter-3 was
selected as the IQ measure. These results can be relevant to
other trials assessing cognitive function in the DS population, but
also in other conditions. Given the breath of these measures we
have validated scales that could be used across trials, including
memory interventions (RBANS, OMQ-PF) as well as in attention
deficits (BRIEF-P, CANTAB spatial span).
CONCLUSION
To our knowledge, the results reported here are the first from a
multinational study assessing cognitive function in a substantial
number of adolescents and adults withDS over a 6-month period,
allowing both robust suitability and reliability analyses. Multiple
assessments that evaluate overlapping cognitive functions were
conducted, which allowed for a robust characterization of
these scales and their interrelationships. Finally, these findings
provide information on the natural neurocognitive changes in
adolescents and adults with DS over a 6-month period, which
will contribute to a better understanding of the true impact of
intervention in future efficacy trials.
Overall, the current study has important implications for
measuring cognitive changes in response to pharmacological
treatment. Such non-pharmacological, longitudinal studies are
key in the development of medicine for neurodevelopmental
disorders such as DS where the choice of appropriate
tools is critical to be able to detect beneficial drug
effects.
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